Journal September 16, 2026 6 min read

Cagrilintide: reported timelines in the literature

A research-supply summary of reported timelines for cagrilintide, a long-acting amylin receptor agonist, covering clinical trial durations, pharmacokinetic study periods, and cross-species mechanistic work.

peptides-pro Editorial

Cagrilintide is a long-acting amylin receptor agonist. It is also referred to as cagrilintide B or cagrilintide D in studies comparing different versions of the molecule. The evidence block does not provide its sequence, molecular formula, or molecular weight. The work described here centres on the amylin receptor, a G-protein-coupled receptor family that includes the calcitonin receptor (Calcr) and receptor activity-modifying proteins such as Ramp3.

Reported timelines for cagrilintide in the literature range from single-dose pharmacokinetic assessments to clinical studies lasting approximately 9 months. The evidence block includes clinical trial registrations with durations of about 8 months, 9 months, 14 weeks, 6 months, and 30 weeks, as well as a cross-species mechanistic study in animals. No human dosing or medical guidance is provided here; this is a research-supply summary.

Research Studies

Cagrilintide and weight management in people with excess body weight

A clinical study compared two different versions of injectable cagrilintide with placebo in people with excess body weight. Participants were randomised to receive either cagrilintide or placebo, and the study lasted about 9 months. The purpose was to assess how well cagrilintide helps people living with excess body weight to lose weight. Cagrilintide is described as a new medicine under development that doctors cannot prescribe yet, but it has been tested in humans before [1].

Cagrilintide and tolerability in participants not tolerating GLP-1 receptor agonists

A clinical study evaluated the safety of cagrilintide compared with placebo in people who do not tolerate marketed glucagon-like peptide-1 (GLP-1) therapies and who live with overweight or obesity. Participants received either cagrilintide or placebo, with treatment assignment decided by chance. The study duration was about 8 months [5].

Cagrilintide and blood levels of two different versions in adults with excess body weight

A clinical study compared blood levels of two different versions of cagrilintide in adults with excess body weight. Participants received either cagrilintide B or cagrilintide D injections, with assignment decided by chance. The study lasted about 14 weeks [6].

Cagrilintide and blood levels after multiple doses of different versions in adults with overweight or obesity

A clinical study tested two versions of cagrilintide to compare their effects in participants with overweight or obesity. Participants received either cagrilintide version D or version B, with assignment decided by chance. The study duration was about 6 months [7].

Cagrilintide and food intake and appetite in people with overweight or obesity

A clinical study investigated how cagrilintide influences food intake and appetite in people with overweight or obesity. Participants received either cagrilintide or placebo, with assignment decided by chance. The study lasted about 30 weeks [8].

Cagrilintide and renal or hepatic impairment

Two studies assessed the effects of renal or hepatic impairment on the pharmacokinetics, safety, and tolerability of subcutaneous cagrilintide. Adult participants were categorised into four groups based on renal or hepatic function (normal function and mild, moderate, or severe impairment) and received a single dose of cagrilintide 0.6 or 0.9 (units not specified in the evidence). Cagrilintide is described as a long-acting amylin agonist under development as monotherapy for weight management and as a fixed-dose combination with the GLP-1 receptor agonist semaglutide (CagriSema) for weight management and treatment of type 2 diabetes [4].

Cagrilintide and the dorsal vagal complex in cross-species models

A cross-species atlas of the dorsal vagal complex examined neural mediators of cagrilintide's effects on energy balance. The study generated a transcriptomics atlas of over 530,000 cells comprising 80 neuronal cell populations across rat, mouse, and macaque caudal brainstem, with spatial profiling to map distribution in the rat dorsal vagal complex (DVC). Cagrilintide regulated two conserved Calcr-expressing DVC neuronal populations. Acute cagrilintide treatment altered gene expression in area postrema Calcr/Ramp3 neurons, but chemogenetic activation in rats failed to affect long-term food intake and body weight. In contrast, long-term cagrilintide treatment in rats upregulated (the evidence block truncates the finding here) [3]. This work is animal-only and does not establish human outcomes.

Cagrilintide and comparative effectiveness in overweight and obesity

A network meta-analysis examined the comparative efficacy and safety of tirzepatide, semaglutide, cagrilintide, and their combination (CagriSema) in the management of overweight and obesity. The authors noted that no direct head-to-head studies have compared all advanced anti-obesity medications. The analysis systematically searched PubMed, Scopus, and Cochrane Central for randomised clinical trials [2]. This is a synthesis of trial data, not a primary study.

Cagrilintide and reported timelines across studies

The table below summarises the reported study durations from the evidence block. Durations are as stated in the source registrations and publications; they are not recommendations for any use.

Study focus	Reported duration	Population or model	Citation
Two versions of injectable cagrilintide vs placebo	About 9 months	People with excess body weight	[1]
Tolerability in participants not tolerating GLP-1 RAs	About 8 months	People with overweight or obesity	[5]
Blood levels of two versions (single dose)	About 14 weeks	Adults with excess body weight	[6]
Blood levels after multiple doses of different versions	About 6 months	Adults with overweight or obesity	[7]
Food intake and appetite	About 30 weeks	People with overweight or obesity	[8]
Renal or hepatic impairment pharmacokinetics	Single dose (duration not specified)	Adults with normal to severe impairment	[4]
Cross-species dorsal vagal complex atlas	Acute and long-term treatment (durations not specified)	Rat, mouse, macaque	[3]

Additional reference-only sources report on amylin-based obesity therapy and CagriSema in type 2 diabetes, but they are not the focus of this timeline summary [9][10][11][12].

If you are reading this for personal health reasons

This material is sold for laboratory research only. We do not provide dosing or medical guidance. Anyone considering a compound for themselves should speak to a licensed clinician.